Bisoprolol
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
- Bisoprolol
- Pharmacist Assessment Report
- Bisoprolol: beta-1 selective adrenergic blocker → malignant hypertensive renal disease
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Bisoprolol: beta-1 selective adrenergic blocker → malignant hypertensive renal disease
One-Sentence Summary
Bisoprolol is a beta-1 selective adrenergic blocker used to lower blood pressure. The TxGNN model predicts it may be relevant to malignant hypertensive renal disease. There are currently no clinical trials and no publications directly studying this disease, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | malignant hypertensive renal disease |
| TxGNN Prediction Score | 0.9994 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Bisoprolol is a beta-1 selective adrenergic blocker, a class that lowers blood pressure and reduces renin release from the kidney.
Malignant hypertensive renal disease is a severe kidney complication of very high, uncontrolled blood pressure. Because bisoprolol lowers blood pressure, a link is plausible. However, the prediction is a computational output only. Acute malignant hypertension is usually managed with intravenous agents, and beta-blockers are not first-line treatment. The score therefore should not be read as evidence of clinical benefit.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for malignant hypertensive renal disease.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 13419G | Bisoprolol generichealth | Tablet containing bisoprolol fumarate 2.5 mg | Not recorded in the local data |
This is a single-ingredient product and it is currently valid.
Safety Considerations
Drug Interactions (100 interactions recorded; examples of those listed):
- Moderate: epinephrine, hydrocortisone, dexamethasone, betamethasone, triamcinolone, budesonide, methscopolamine, hyoscyamine, atropine, bupropion, morphine, acetohexamide, and several calcium salts (acetate, carbonate, citrate, gluconate, glubionate)
- Minor: acetylsalicylic acid, aluminium hydroxide, attapulgite
For warnings, contraindications and other safety information, please refer to the TGA-approved Product Information (PI).
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high (0.9994), but no clinical trials or publications address malignant hypertensive renal disease, so the evidence level is L5. Beta-blockers are also not first-line therapy for this acute condition.
To proceed, the following is needed:
- Clinical or observational studies of bisoprolol in malignant hypertension with renal involvement
- Mechanism of action data for bisoprolol
- Review of the TGA Product Information for warnings and contraindications
- Assessment of how bisoprolol would fit alongside standard intravenous management of malignant hypertension
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.